Macquarie Group Ltd. bought a new stake in Medpace Holdings Inc (NASDAQ:MEDP) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 5,100 shares of the company’s stock, valued at approximately $334,000.
Other hedge funds have also recently made changes to their positions in the company. Pearl River Capital LLC purchased a new stake in shares of Medpace in the second quarter valued at about $27,000. FTB Advisors Inc. lifted its holdings in shares of Medpace by 171.8% in the second quarter. FTB Advisors Inc. now owns 579 shares of the company’s stock worth $37,000 after buying an additional 366 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Medpace by 53.9% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after buying an additional 212 shares in the last quarter. Advisor Group Inc. lifted its holdings in shares of Medpace by 18.7% in the second quarter. Advisor Group Inc. now owns 1,462 shares of the company’s stock worth $95,000 after buying an additional 230 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Medpace in the first quarter worth about $99,000. Institutional investors own 83.45% of the company’s stock.
A number of equities research analysts have recently issued reports on MEDP shares. Credit Suisse Group increased their price target on shares of Medpace from $65.00 to $77.00 and gave the stock an “outperform” rating in a report on Tuesday, July 30th. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday. SunTrust Banks increased their price target on shares of Medpace to $85.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a report on Friday, October 4th. Finally, ValuEngine downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $78.00.
Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 29th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.18. The business had revenue of $214.10 million for the quarter, compared to the consensus estimate of $200.99 million. Medpace had a net margin of 11.28% and a return on equity of 17.65%. Medpace’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the firm posted $0.61 earnings per share. On average, equities analysts anticipate that Medpace Holdings Inc will post 2.91 earnings per share for the current year.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Cost of Capital Explained
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.